首页    期刊浏览 2024年09月15日 星期日
登录注册

文章基本信息

  • 标题:Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
  • 本地全文:下载
  • 作者:Juan F. Alcala-Diaz ; Laura Limia-Perez ; Ricardo Gomez-Huelgas
  • 期刊名称:Nutrients
  • 电子版ISSN:2072-6643
  • 出版年度:2021
  • 卷号:13
  • 期号:6
  • 页码:1760
  • DOI:10.3390/nu13061760
  • 出版社:MDPI Publishing
  • 摘要:Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.
  • 关键词:COVID-19; calcifediol; SARS-CoV-2; COVID-19 drug treatment; vitamin D COVID-19 ; calcifediol ; SARS-CoV-2 ; COVID-19 drug treatment ; vitamin D
国家哲学社会科学文献中心版权所有